EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced today that the company has received $1.7M funding approval from the U.S. Department of Defense to support the development of biologic-based monoclonal antibody (mAb) therapies against staphylococcal-derived pathogens.
